MedTrace Logo

Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus

NCT03654313 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2020-08-24

No results posted yet for this study

Summary

To evaluate the safety, tolerability, PK and immunogenicity of single and multiple ascending doses of MEDI6570 in subjects with Type 2 Diabetes Mellitus

Conditions

Interventions

BIOLOGICAL

MEDI6570

MEDI6570

BIOLOGICAL

Placebo

Placebo

BIOLOGICAL

Part B Placebo

Placebo

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • Marvin Sinsakul · MedImmune LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-28
Primary Completion
2020-07-21
Completion
2020-07-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03654313 on ClinicalTrials.gov